RSPI Stock - RespireRx Pharmaceuticals Inc.
Unlock GoAI Insights for RSPI
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-1,579,355 | $-2,559,128 | $-3,315,135 | $-1,736,504 | $-2,176,524 |
| Net Income | $-2,102,720 | $-3,869,609 | $-4,846,886 | $-2,519,694 | $-2,591,790 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-0.04 | $-0.22 | $-6.45 | $-7.73 |
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
Visit WebsiteEarnings History & Surprises
RSPIEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 17, 2023 | — | $-0.00 | — | — |
Q3 2023 | Aug 21, 2023 | — | $-0.00 | — | — |
Q2 2023 | May 22, 2023 | — | $-0.01 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q4 2022 | Nov 17, 2022 | — | $-0.01 | — | — |
Q3 2022 | Aug 22, 2022 | — | $-0.01 | — | — |
Q2 2022 | May 23, 2022 | — | $-0.01 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.01 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.01 | — | — |
Q2 2021 | May 24, 2021 | — | $-0.01 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.05 | — | — |
Q4 2020 | Nov 23, 2020 | — | $-0.10 | — | — |
Q3 2020 | Aug 19, 2020 | — | $-0.10 | — | — |
Q2 2020 | May 20, 2020 | — | $-1.40 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-1.62 | — | — |
Q4 2019 | Nov 19, 2019 | — | $-1.20 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-1.23 | — | — |
Q2 2019 | May 20, 2019 | — | $-1.40 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-1.98 | — | — |
Latest News
Frequently Asked Questions about RSPI
What is RSPI's current stock price?
What is the analyst price target for RSPI?
What sector is RespireRx Pharmaceuticals Inc. in?
What is RSPI's market cap?
Does RSPI pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to RSPI for comparison